Business Wire

Merck Completes € 180 Million Investment to Expand Schnelldorf Distribution Center

Share

Merck, a leading science and technology company, has opened its newly expanded Life Science distribution center in Schnelldorf, Germany. The investment of € 180 million added 25,000 square meters to the site, almost doubling its size. It now includes a new manual down filling operation and additional space for the distribution of a wide range of products to laboratories and research facilities all around the world. The site employs 470 engineers, manufacturing and distribution experts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240606764930/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Merck opens newly expanded Life Science distributed center, with added downfilling capabilities in Schnelldorf, Germany. (Photo: Business Wire)

“By combining manual downing filling capabilities with our distribution expertise, our customers will benefit from increased product availability and quicker delivery,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science. “This is critical to ensuring that medicines reach patients faster, safely, and more efficiently. This is how we do our part to impact life and health with science.”

"With this expansion, Schnelldorf is becoming one of our flagship sites, providing unique end-to-end capabilities for our Life Science customers" said Ivan Donzelot, Head of Integrated Supply Chain Operations, Life Science. “With the full integration of manufacturing and distribution in one site, our customers can now receive even faster and better service whether they are in Europe or in other regions of the world.”

The expansion of the Schnelldorf facility is part of a multi-year investment program of Merck’s Life Science business sector. It aims to increase the capacity and capabilities to support the growing global demand for critical drugs and to make significant contributions to public health. Since 2020, Merck has announced industrial capacity and capabilities expansion projects in Life Science throughout Europe, China, and the United States, of more than € 2 billion.

The Life Science Business of Merck is comprised of more than 50 production and testing sites and 64 distribution centers around the world and has more than 27,000 employees in 65 countries.

About Merck

Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.

All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations
Rachel Bloom Baglin
rachel.bloom-baglin@merckgroup.com
Phone: +49 (6151) 72-44461

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

DentalMonitoring Sets New Standard in Orthodontic Remote Monitoring With EU-MDR Certification14.6.2024 20:33:00 EEST | Press release

DentalMonitoring is proud to announce that the DentalMonitoring Software is now certified under the European Union Medical Device Regulation 2017/745 (EU MDR) and fulfills the requirements for CE marking as a class IIa medical device. European Medical Device Regulation 2017/745 (EU MDR) replaces the previous Medical Device Directive 93/42/EEC (MDD). EU MDR sets more rigorous requirements for clinical evaluation, risk management, post-market surveillance, and data collection on medical devices.(1) This landmark achievement underscores DentalMonitoring's commitment to advancing dental care through cutting-edge technology and rigorous regulatory compliance. Achieving this certification four years ahead of the deadline demonstrates DentalMonitoring's commitment to positioning itself as an innovative, serious, efficient, and safe player in the medical field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240614842101/en/ DentalMo

Argonne and a Moroccan University Sign Agreement to Advance Green Energy Tech and Computing14.6.2024 16:24:00 EEST | Press release

The U.S. Department of Energy’s (DOE) Argonne National Laboratory and University Mohammed VI Polytechnic (UM6P) have signed a memorandum of understanding (MOU) to collaborate on key areas of mutual interest related to green energy technology and the nexus of water and energy. In a ceremony held at UM6P’s campus in Benguerir, the MOU was signed by Argonne Laboratory Director Paul Kearns and UM6P President Hicham El Habti. “We are excited to see what discoveries and innovations will result from our ongoing partnership,” said Kearns. ​“By working together, we’ll open new scientific frontiers for both our countries’ futures.” “Today marks a significant milestone in our journey towards sustainable innovation. The signing of this Memorandum of Understanding with Argonne National Laboratory underscores our commitment to advancing research and development in renewable energy, energy grids, and water management. Together, we aim to leverage our collective expertise to create transformative solu

MultiBank Group Recognized as Top BaFin-Regulated Forex Broker14.6.2024 15:33:00 EEST | Press release

MultiBank Group is thrilled to announce its recognition as a top BaFin-regulated forex broker by FXEmpire, a leading financial markets authority. This prestigious accolade highlights MultiBank Group's unwavering commitment to excellence, security, and innovation in the forex trading industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240614306878/en/ Top BaFin regulated forex broker 2024 (Graphic: Business Wire) About BaFin: Regulating German Financial Markets BaFin, Germany's Federal Financial Supervisory Authority, oversees the country's banking, securities, and insurance sectors. It ensures fair and transparent operations in the forex and CFD markets by enforcing rigorous standards. Selection Methodology FXEmpire's methodology for selecting the best BaFin-regulated brokers includes: Regulation Verification: Ensuring each broker is BaFin-regulated, providing traders with high-level protection. Cost Efficiency: Brokers

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)14.6.2024 15:00:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers. If exercised, the option would allow Takeda to license global rights to develop and commercialize olverembatinib in all territories outside of mainland China, Hong Kong, Macau, Taiwan and Russia. Despite the impact TKIs have had in the treatment of patients with CML, there remains significant unmet need for patients whose disease is resistant or refractory to these therapies or who develop hard-to-treat mutations following these treatments. “Takeda has a long history of driving important treatment advances for patients, particularly those with hematological cancers facing treatment gaps,” said Teresa Bitetti, president of the Globa

SLB and Aker Carbon Capture Announce Closing of Carbon Capture Joint Venture14.6.2024 13:30:00 EEST | Press release

Regulatory News: SLB (NYSE: SLB) and Aker Carbon Capture (ACC) announced today the closing of their previously announced joint venture. The new company combines technology portfolios, expertise and operations platforms to support accelerated carbon capture adoption for industrial decarbonization at scale. “There is no credible pathway toward net zero without deploying carbon capture and sequestration (CCS) at scale,” said Gavin Rennick, president of SLB’s New Energy business. “In the next few decades, many industries that are crucial to our modern world must rapidly adopt CCS to decarbonize. Through the joint venture, we are excited to accelerate disruptive carbon capture technologies globally.” The new company will combine ACC’s amine-based Advanced Carbon Capture™ technologies, including Just Catch™ and Big Catch™ modular plant technologies for medium- and large-scale facilities, and Just Catch Offshore™ for offshore gas turbines, with SLB’s portfolio of technology solutions, includi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye